as 05-20-2024 1:34pm EST
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Founded: | 2017 | Country: | United States |
Employees: | 44 | City: | LA JOLLA |
Market Cap: | 55.0M | IPO Year: | 2018 |
Target Price: | $3.90 | AVG Volume (30 days): | 206.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.35 | EPS Growth: | N/A |
52 Week Low/High: | $0.45 - $3.25 | Next Earning Date: | 05-09-2024 |
Revenue: | $37,894,000 | Revenue Growth: | 53.80% |
Revenue Growth (this year): | 8.56% | Revenue Growth (next year): | 6.05% |
EQ Breaking Stock News: Dive into EQ Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Zacks
11 days ago
Business Wire
11 days ago
Business Wire
13 days ago
Simply Wall St.
18 days ago
Business Wire
2 months ago
Zacks
2 months ago
Business Wire
2 months ago